Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Operating expenses:
Research and development	$ 6,619,597	$ 5,751,940
General and administrative	4,834,284	6,167,177
Goodwill impairment		6,929,258
Depreciation	97,915	110,371
Loss from operations	11,551,796	18,958,746
Other expense (income):
Interest (income) expense, net	(85,302)	(151,647)
Loss from operations before income taxes	(11,466,494)	(18,807,099)
Income tax expense (benefit)	332,885	(437,289)
Net loss	(11,799,379)	(18,369,810)
Accretion of Series A cumulative preferred dividends		(85,993)
Deemed dividend related to the make-whole provision for the conversion of Series A convertible preferred stock into common stock		(8,167,895)
Net loss attributable to common stockholders	$ (11,799,379)	$ (26,623,698)
Per share information:
Net loss per share of common stock, basic and diluted (in dollars per share)	$ (1.76)	$ (8.21)
Weighted average shares outstanding, basic and diluted (in dollars per share)	$ 6,706,509	$ 3,242,301